DealsJul 14, 2026, 06:46 AM
AstraZeneca Licenses Zegfrovy for Lung Cancer; $600M Upfront
AI Summary
AstraZeneca has entered an exclusive global license agreement with Dizal Pharmaceutical for Zegfrovy (sunvozertinib), a novel oral EGFR inhibitor for lung cancer. AstraZeneca will acquire worldwide rights to develop and commercialize Zegfrovy, which is approved in the US and China for locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. The deal includes an upfront payment of $600 million and up to $900 million in milestone payments, plus tiered royalties. This acquisition strengthens AstraZeneca's leading portfolio in EGFR-mutated lung cancer.
Key Highlights
- AstraZeneca entered an exclusive global license agreement for Zegfrovy (sunvozertinib).
- Upfront payment of $600 million to Dizal Pharmaceutical.
- Additional payments of up to $900 million upon achievement of milestones.
- Dizal will receive tiered royalties on global sales of Zegfrovy.
- Zegfrovy is approved in the US and China for NSCLC with EGFR exon 20 insertion mutations.
- Positive Phase III results for 1st-line NSCLC with exon 20 insertion EGFR mutations.
- Transaction expected to close in the second half of 2026.
Price Impact
More from AZN